

E2B FILE

Company Name	Comment
sanofi	
Reference Number	
CE2B2/2018	
e2b_file	
kmtisi.xml	

E2B Content

```
<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE ichicsr SYSTEM "http://eudravigilance.ema.europa.eu/dtd/icsr21.xml.dtd"> <ichicsr lang="en"> <ichicsrmessageheader> <messagetype>ichicsr</messagetype> <messageformatversion>2.1</messageformatversion> <messageformatrelease>2.0</messageformatrelease> <messagenumb>265123_OBT</messagenumb> <messagesenderidentifier>SAAVTEST</messagesenderidentifier> <messagereceiveridentifier>ZWE_TEST</messagereceiveridentifier> <messagedateformat>204</messagedateformat> <messagedate>20180430172702</messagedate> </ichicsrmessageheader> <safetyreport> <safetyreportversion>1</safetyreportversion> <safetyreportid>ZW-SANOFI S.A.-2018SA000254</safetyreportid> <primarysourcecountry>ZW</primarysourcecountry> <occurcountry>ZW</occurcountry> <transmissiondateformat>102</transmissiondateformat> <transmissiondate>20180430</transmissiondate> <reporttype>1</reporttype> <serious>1</serious> <seriousnessdeath>2</seriousnessdeath> <seriousnesslifethreatening>2</seriousnesslifethreatening> <seriousnesshospitalization>2</seriousnesshospitalization> <seriousnessdisabling>2</seriousnessdisabling> <seriousnesscongenitalanomaly>2</seriousnesscongenitalanomaly> <seriousnessother>1</seriousnessother> <receivedateformat>102</receivedateformat> <receivedate>20180424</receivedate> <receiptdateformat>102</receiptdateformat> <receiptdate>20180424</receiptdate> <additionaldocument>2</additionaldocument> <fulfillexpeditecriteria>1</fulfillexpeditecriteria> <companynumb>ZW-SANOFI S.A.-2018SA000254</companynumb> <medicallyconfirm>1</medicallyconfirm> <linkedreport> <linkreportnumb>US-SA-2017SA000001</linkreportnumb> </linkedreport> <primarysource> <reporterfamilyname>PRIVACY</reporterfamilyname> <reportercountry>ZW</reportercountry> <qualification>1</qualification> <literaturereference>Nguyen TP, Takiar V, Garden AS et al.. Reirradiation of Head and Neck cancers with protons therapy : outcomes and Analyses. International. Journal of Radiation Oncology Biology Physics. 2016;96(1):30-35</literaturereference> </primarysource> <sender> <sendertype>1</sendertype> <senderorganization>SAAVTEST</senderorganization> <senderdepartment>Global Pharmacovigilance and Epidemiology</senderdepartment> <senderstreetaddress>1, avenue Pierre Brossolette</senderstreetaddress> <sendercity>Chilly-Mazarin</sendercity> <senderpostcode>91385</senderpostcode> <sendercountrycode>FR</sendercountrycode> <sendertel>999TEST</sendertel> <sendertelexextension>9TEST</sendertelexextension> <sendertelcountrycode>33</sendertelcountrycode> <senderfax>999TEST</senderfax> <senderfaxextension>9TEST</senderfaxextension> <senderfaxcountrycode>33</senderfaxcountrycode> <senderemailaddress>1050@foresightgroup.com</senderemailaddress> </sender> <receiver> <receivertype>2</receivertype> <receiverorganization>ZWE_TEST</receiverorganization> <receivercountrycode>ZW</receivercountrycode> <receivertel>999TEST</receivertel> <receivertelexextension>9TEST</receivertelexextension> <receiverfax>999TEST</receiverfax> <receiverfaxextension>9TEST</receiverfaxextension> <receiveremailaddress>1050@foresightgroup.com</receiveremailaddress> </receiver> <patient> <patientinitial>PRIVACY</patientinitial> <patientinvestigationnumb>-</patientinvestigationnumb> <patientonsetage>30</patientonsetage> <patientonsetageunit>801</patientonsetageunit> <patientagegroup>5</patientagegroup> <patientsex>1</patientsex> <resultstestsprocedures>Test Name: Full blood count,Date: , Result: 224 IU, Notes: ; </resultstestsprocedures> <parent> <parentidentification>PRIVACY</parentidentification> </parent> <reaction> <primarysourcereaction>insomnia</primarysourcereaction> <reactionmeddraversionllt>20.1</reactionmeddraversionllt> <reactionmeddrallt>10022437</reactionmeddrallt> <reactionmeddraversionnpt>20.1</reactionmeddraversionnpt> <reactionmeddrapt>10022437</reactionmeddrapt> <termhighlighted>4</termhighlighted> <reactionoutcome>2</reactionoutcome> </reaction> <test> <testname>10017411</testname> <testresult>224</testresult> <testunit>IU</testunit> <lowtestrange>20</lowtestrange> <hightestrange>30</hightestrange> <moreinformation>2</moreinformation> </test> <drug> <drugcharacterization>1</drugcharacterization> <medicinalproduct>PLAVIX</medicinalproduct> <obtaindrugcountry>ZW</obtaindrugcountry> <drugbatchnumb>102</drugbatchnumb> <drugauthorizationcountry>ZW</drugauthorizationcountry> <drugstructuredosagenumb>10</drugstructuredosagenumb> <drugstructuredosageunit>012</drugstructuredosageunit> <drugcumulativedosagenumb>5</drugcumulativedosagenumb> <drugcumulativedosageunit>003</drugcumulativedosageunit> <drugdosagetext>10 ml, TOTAL</drugdosagetext> <drugdosageform>Film-coated tablet</drugdosageform> <drugstartdateformat>102</drugstartdateformat> <drugstartdate>20180419</drugstartdate> <drugenddateformat>102</drugenddateformat> <drugenddate>20180421</drugenddate> <drugtreatmentduration>3</drugtreatmentduration> <drugtreatmentdurationunit>804</drugtreatmentdurationunit> <actiondrug>5</actiondrug> <drugadditional>ExpDT=21-APR-2018</drugadditional>
```

<activesubstance> <activesubstancename>CLOPIDOGREL BISULFATE</activesubstancename> </activesubstance> <drugreactionrelatedness>
<drugreactionassesmeddraversion>20.1</drugreactionassesmeddraversion> <drugreactionasses>10022437</drugreactionasses>
<drugassessmentsource>Health Care professional</drugassessmentsource> <drugassessmentmethod>Global
Introspection</drugassessmentmethod> <drugresult>Related</drugresult> </drugreactionrelatedness> <drugreactionrelatedness>
<drugreactionassesmeddraversion>20.1</drugreactionassesmeddraversion> <drugreactionasses>10022437</drugreactionasses>
<drugassessmentsource>Pharmaceutical Company</drugassessmentsource> <drugassessmentmethod>Global
Introspection</drugassessmentmethod> <drugresult>Related</drugresult> </drugreactionrelatedness> </drug> <summary>
<narrativeincludeclinical>This is a Narrative section.</narrativeincludeclinical> </summary> </patient> </safetyreport> </ichicsr>